November is #NationalFamilyCaregiversMonth, a time to honor and celebrate the incredible #caregivers who provide invaluable support to the #hyperinsulinism community.

Hear more from caregivers here: bit.ly/46IK51G

#Rezolute #congenitalHI #tumorhyperinsulinism #raredisease #MedSky #EndoSky #PedSky

Today is #WorldPancreaticCancerDay, and we're shining a light on #insulinomas - a rare type of tumor that usually forms from the insulin-secreting cells in the pancreas, resulting in hypoglycemia.

Explore how #Rezolute is working to shape the future of #hyperinsulinism: bit.ly/46IK51G
#MedSky

#Rezolute is proud to support Neuroendocrine Cancer Awareness Day! Neuroendocrine tumors (NETs) can have a profound impact on patients’ lives, so join us in raising awareness and supporting those affected by NET cancers.
#LetsTalkAboutNETs #NETCancerDay #tumorhyperinsulinism #OncSky #EndoSky #MedSky

This is an incredible outcome, representative of the Agency's recognition of ersodetug as a potential universal treatment for multiple forms of HI, and the high unmet need in this patient population. #EndoSky #MedSky #OncSky #RareDisease #Hyperinsulinism #TumorHI

Proud to present "Preliminary Patient Demographics and Baseline Characteristics From a Phase 3 Study (sunRIZE) of Ersodetug for Hypoglycemia Due to Congenital Hyperinsulinism: Trial in Progress" today at #ENDO2025. View the full poster here: bit.ly/44x4GF6 #EndoSky #MedSky #CongenitalHi #RZLT

We're thrilled to present “Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress" at #ENDO2025 in San Francisco! #ENDO #MedSky #PedSky #CongenitalHI #RZLT #biotech

Online Now: Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinism

Dive into the latest issue to reacquaint yourself with our Phase 2b (RIZE) study on congenital hyperinsulinism and see the science behind the visuals! (4/4) www.sciencedirect.com/science/arti...
#MedSky #PedSky #CongenitalHI #Ersodetug #Hyperinsulinism #Hypoglycemia #RareDisease

Why is this illustration powerful
•Shares insights into ersodetug’s MOA
•Provides visual context for the powerful science described in the RIZE Study results in this issue of Med
•Highlights ersodetug’s effects downstream of the pancreas making it a potential therapy for all forms of hyperinsulinism

🎨 Cover Art Reveal: Unpacking the Science 🧬
Checkout Med’s journal cover this month, which illustrates Ersodetug as an insulin receptor modulating antibody (1/4)
#Med #Ersodetug #MOA #RareDisease #Hyperinsulinism #CongenitalHI #Hypoglycemia #ScientificArt #VisualStorytelling #MedSky